<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04996758</url>
  </required_header>
  <id_info>
    <org_study_id>B2021-055</org_study_id>
    <nct_id>NCT04996758</nct_id>
  </id_info>
  <brief_title>Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)</brief_title>
  <official_title>Open-Label, Phase Ⅱ Study of Toripalimab and Anlotinib Combination Treatment in Patients With Recurrent or Metastatic Nasopharyngeal Carcinoma After Failure of at Least One Line of Platinum-Based Chemotherapy (TORAL)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sun Yat-sen University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sun Yat-sen University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase 2 trial studies toripalimab and anlotinib combination treatment in patients with&#xD;
      recurrent or metastatic nasopharyngeal carcinoma after failure of at least one line of&#xD;
      platinum-based chemotherapy&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">August 2028</completion_date>
  <primary_completion_date type="Anticipated">August 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Objective Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Objective Response rate will be determined on the basis of investigator assessments</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Disease Control rate</measure>
    <time_frame>2 years</time_frame>
    <description>the proportion of patients who had a best response rating of complete response, partial response, or stable disease will be determined on the basis of investigator assessments</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the start of treatment to the progression of the tumor or death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the start of treatment to time of death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Complete Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Complete Response rate will be determined on the basis of investigator assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Partial Response rate</measure>
    <time_frame>2 years</time_frame>
    <description>Partial Response rate will be determined on the basis of investigator assessments</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>5 years</time_frame>
    <description>The time from the first assessment of complete remission or partial remission to progressive disease or death (due to any cause).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Participants With Adverse Events</measure>
    <time_frame>5 years</time_frame>
    <description>Adverse Events will be determined and graded on the basis of investigator assessments according to NCI CTC AE 5.0</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">39</enrollment>
  <condition>Nasopharyngeal Carcinoma</condition>
  <condition>Recurrent or Metastatic Nasopharyngeal Carcinoma</condition>
  <arm_group>
    <arm_group_label>Toripalimab and Anlotinib Combination Treatment</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive toripalimab at a dose of 240 mg on day 1 and anlotinib at a dose of 12 mg before breakfast for once-daily on days 1-14. Treatment cycles repeat every 21 days in the absence of disease progression or unacceptable toxicity</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Toripalimab and Anlotinib</intervention_name>
    <description>Toripalimab 240 mg iv.drip d1; Anlotinib 12mg po qd d1-14.</description>
    <arm_group_label>Toripalimab and Anlotinib Combination Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histologically confirmed undifferentiated non-keratinizing carcinoma&#xD;
&#xD;
          -  Patients suffered failure of at least one line of platinum-based chemotherapy. The&#xD;
             definition of treatment failure: progression during or after chemotherapy for&#xD;
             recurrence/metastasis; progression after concurrent chemoradiotherapy within 6 months.&#xD;
             Withdrawal of treatment due to drug intolerances is excluded ;&#xD;
&#xD;
          -  Without other malignancy;&#xD;
&#xD;
          -  Male or female, 18-70 years;&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) of 0-2;&#xD;
&#xD;
          -  Life expectancy ≥ 3 months;&#xD;
&#xD;
          -  Women of childbearing age must obtain the negative result of a pregnancy test (serum&#xD;
             or urine) , and they were willing to use reliable methods of contraception during the&#xD;
             trial;&#xD;
&#xD;
          -  At least one evaluable lesion；&#xD;
&#xD;
          -  Laboratory tests meet the following standards:&#xD;
&#xD;
        Blood routine: White blood cell count (WBC) ≥3.0×10 9 /L, neutrophil count (ANC) ≥1.5×10 9&#xD;
        /L, platelet count (PLT) ≥75×10 9 /L, hemoglobin (HGB) 90 g/L or higher; Liver function:&#xD;
        total bilirubin ≤1.5 times the upper limit of normal (ULN); glutamic-oxalacetic&#xD;
        transaminase (AST) and alanine transaminase (ALT) ≤2.5 times ULN, AST and ALT ≤2.5 times&#xD;
        ULN for the patients with liver metastases; Alkaline phosphatase ≤5 times ULN; Renal&#xD;
        function: Serum creatinine (Cr) ≤1.5 times ULN; Creatinine clearance ≥60mL/min; Urine&#xD;
        routine: urine protein &lt;2+ ;baseline urine protein ≥2+ and 24 hours urine protein &lt; 1g ;&#xD;
        Coagulation: International normalized ratio (INR) and activated partial thrombin time&#xD;
        (APTT) ≤1.5 times ULN; Albumin ≥28g/L Thyroid stimulating hormone (TSH)≤1 times ULN (free&#xD;
        triiodothyrosine [FT3] or free thyroxine [FT4] ≤1 times ULN can be included)&#xD;
&#xD;
          -  No serious cardiopulmonary dysfunction;&#xD;
&#xD;
          -  The informed consent has been signed.&#xD;
&#xD;
          -  Ability to comply with test requirements&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  A known allergy to any of the drugs in the study;&#xD;
&#xD;
          -  Pregnant or breastfeeding women;&#xD;
&#xD;
          -  Participated in clinical trials of other drugs within 4 weeks prior to study&#xD;
             initiation;&#xD;
&#xD;
          -  Previous treatment with bevacizumab or VEGFR-family small molecule tyrosine kinase&#xD;
             inhibitors (e.g., famitinib, sorafenib, Sunitinib, regofinib, Apatinib, Anlotinib,&#xD;
             fuquinitinib) ;&#xD;
&#xD;
          -  Recurrent nasopharyngeal lesions after radiotherapy and who received secondary&#xD;
             radiotherapy;&#xD;
&#xD;
          -  Palliative radiotherapy for symptom control within 28 days before enrollment;&#xD;
&#xD;
          -  Immunosuppressive treatment with immunosuppressive agent, systemic or absorbable&#xD;
             topical hormone therapy ( prednisone or other therapeutic hormone at the dose greater&#xD;
             than 10mg/ day) within 2 weeks before enrollment;&#xD;
&#xD;
          -  Active autoimmune diseases, with the necessity of systemic treatment (hormone&#xD;
             replacement therapy is not considered as a systemic treatment, such as type 1&#xD;
             diabetes) over the past two years; autoimmune diseases that did not require systemic&#xD;
             treatment in the past two years;&#xD;
&#xD;
          -  A history of immunodeficiency, including acquired/congenital immunodeficiency&#xD;
             disorders, a history of organ transplantation;&#xD;
&#xD;
          -  Vaccinated with live vaccine (inactivated virus vaccine for seasonal influenza is&#xD;
             allowed) within 4 weeks before enrollment;&#xD;
&#xD;
          -  Invasion of important vessels (e.g. surrounding internal carotid artery/vein) on MRI;&#xD;
             tumor with a high risk of affecting vital blood vessels during treatment and causing&#xD;
             fatal hemorrhage, which is determined by investigators;&#xD;
&#xD;
          -  A history of severe bleeding and any bleeding event with a severity rating of 3 or&#xD;
             higher in the NCI CTCAE within 4 weeks prior to screening;&#xD;
&#xD;
          -  Abnormal coagulation (INR &gt; 2.0, PT &gt; 16s) and bleeding tendency (the INR must be&#xD;
             within the normal range without anticoagulants during14 days prior to signing the&#xD;
             informed consent); patients treated with anticoagulants or vitamin K antagonists such&#xD;
             as warfarin, heparin, or their analogests; low-dose warfarin (1 mg orally, once daily)&#xD;
             or low-dose aspirin (up to 100 mg daily) for preventive purposes, provided that the&#xD;
             international normalized ratio of prothrombin time (INR) is ≤ 1.5;&#xD;
&#xD;
          -  Unstable angina and/or congestive heart failure or vascular disease with the need of&#xD;
             hospital treatment; other cardiac damage that may affect the drug safety;&#xD;
&#xD;
          -  Patients with hypertension that is not well controlled with antihypertensive&#xD;
             medication (systolic &gt; 140mmHg, diastolic &gt; 90 mmHg); patients is taking a combination&#xD;
             of two or more antihypertensive drugs; Cardiovascular disease with clinical&#xD;
             significance， such as cerebrovascular accident (≤ 6 months before randomization),&#xD;
             myocardial infarction (≤ 6 months before randomization), unstable angina, congestive&#xD;
             heart failure of NYHA grade II or higher, or severe arrhythmias that cannot be&#xD;
             controlled with drugs or have a potential impact on experimental treatments;&#xD;
&#xD;
          -  Patients with esophageal and gastric varices, active ulcers, intestinal perforation or&#xD;
             intestinal obstruction within 6 months before enrollment;&#xD;
&#xD;
          -  A history of abdominal fistula, digestive tract perforation, intra-abdominal abscess&#xD;
             or acute gastrointestinal bleeding within 6 months before enrollment;&#xD;
&#xD;
          -  Multiple factors affecting oral administration and absorption of drugs (e.g.,&#xD;
             inability to swallow, post-gastrointestinal resection, chronic diarrhea and intestinal&#xD;
             obstruction);&#xD;
&#xD;
          -  Overoperation/venous thromboembolism events, NCI CTCAE grade 3 or higher venous&#xD;
             thromboembolism within 6 months before enrollment, such as cerebrovascular accident&#xD;
             (including temporary ischemic attack), deep venous thrombosis (except for those venous&#xD;
             thrombosis caused by venous catheterization due to previous chemotherapy and&#xD;
             determined to be cured by the researchers ), pulmonary embolism, etc.;&#xD;
&#xD;
          -  Patients with past and present objective evidence of pulmonary fibrosis, interstitial&#xD;
             pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, or severe&#xD;
             impairment of lung function;&#xD;
&#xD;
          -  Exacerbation of chronic obstructive pulmonary disease (COPD) or other respiratory&#xD;
             disease requiring hospitalization within 28 days before enrollment;&#xD;
&#xD;
          -  Active pulmonary infection and/or acute bacterial or fungal infection requiring&#xD;
             intravenous antibiotic treatment within 28 days;&#xD;
&#xD;
          -  Dominant jaundice due to abnormal liver function within 7 days;&#xD;
&#xD;
          -  Renal insufficiency: routine urinalproteinuria &gt; 2+ and confirmed 24 h urinary protein&#xD;
             quantification &gt; 1.0g;&#xD;
&#xD;
          -  Minor surgical operations (including catheterization, excluding central venous&#xD;
             catheterization via peripheral venipuncture) within 2 days before enrollment;&#xD;
&#xD;
          -  Major surgery within 28 days before enrollment;&#xD;
&#xD;
          -  A potent CYP3A4 inhibitor within one week prior to enrollment, or a potent CYP3A4&#xD;
             inducer within two weeks prior to study participation&#xD;
&#xD;
          -  Long-term unhealed wounds or incomplete fractures;&#xD;
&#xD;
          -  Symptomatic central nervous system metastases (e.g. brain edema, need for hormonal&#xD;
             intervention, or brain metastases)&#xD;
&#xD;
          -  The presence of serious or uncontrolled infections;&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 5, 2021</study_first_submitted>
  <study_first_submitted_qc>August 5, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 9, 2021</study_first_posted>
  <last_update_submitted>August 5, 2021</last_update_submitted>
  <last_update_submitted_qc>August 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Sun Yat-sen University</investigator_affiliation>
    <investigator_full_name>Qingqing Cai</investigator_full_name>
    <investigator_title>Chief physician</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

